Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | HBB | P68871 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ADK | P55263 | 12/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14201487 | 1.00 | LMNA (0.58) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL12616703 | 1.00 | LMNA (0.58) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL14388655 | 1.00 | LMNA (0.58) | LMNATSHRMAPTPMP22HBB | |
| Doxifluridine SCHEMBL27598202 | 0.86 | LMNA (0.58) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL19657131 | 0.85 | LMNA (0.56) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL10013535 | 0.85 | LMNA (0.56) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL331945 | 0.85 | LMNA (0.56) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL12029778 | 0.85 | LMNA (0.56) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL15119375 | 0.85 | LMNA (0.56) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL2467656 | 0.85 | LMNA (0.56) | LMNATSHRMAPTPMP22HBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224422-A1 | PREPARATION OF CAPECITABINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224422-A1 | PREPARATION OF CAPECITABINE | DPYD, TYMP, DCTD | LMNA 2368/4885TSHR 4324/4885MAPT 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.